The Triple Agonist on the Runway — and the Patient We're Watching For

We've started going through the active weight management cohort identifying the subset who would be retatrutide candidates the moment access materializes. Most folks don't make the list. Tirzepatide is and will remain the foundational metabolic peptide for our program — its dual GLP-1/GIP mechanism is doing the bulk of the work the typical metabolic patient needs, and the safety, dosing, and access picture after several years of real-world use is increasingly clear.

But there's a slice — somewhere in the 10–20% range of our active cohort, working estimate — where tirzepatide's ceiling isn't appetite or glycemia but residual hepatic adiposity, persistent atherogenic lipid signal despite respectable weight loss, or BMI-driven cardiometabolic risk that hasn't fully resolved. The shared mechanistic gap: the glucagon arm. Tirzepatide doesn't have one.

So the question we're working in real time: who, in our chart, fits the phenotype where adding glucagon-receptor agonism plausibly moves the residual disease — high BMI (typically above 35), MASLD signal on imaging or labs, ApoB and non-HDL-C still elevated after weight loss has plateaued, hepatic function intact, no severe rhythm or heart-rate issue. Those are the folks we want flagged before broader access lands so the conversation is ready, not improvised.

The current posture is identification, not initiation. We are watching the TRIUMPH program readouts, modeling the access path through our compounding partners for when the molecule and the indication line up, and building the cohort list now so we move with the evidence rather than the buzz. When retatrutide is the right answer for a specific patient, we expect to use it — including in the compounded format, if that is where access lands first and the data supports it. For the bulk of our cohort, that conversation is not this year's conversation.

Two FDA-approved drugs anchor the incretin class today.

Semaglutide — sold under Ozempic and Wegovy as injections, and Rybelsus as an oral pill — was the first-in-class breakthrough. It is a selective agonist of the GLP-1 receptor: appetite suppression, slowed gastric emptying, glucose-dependent insulin release. Most folks who have ever taken a "GLP-1 drug" took semaglutide.

Tirzepatide — sold as Mounjaro for diabetes and Zepbound for weight management — added the GIP receptor to the same backbone. Two receptors instead of one, with a layered effect: more weight loss in the trials, fewer GI side effects than the dose-equivalent semaglutide, better glycemic control. Tirzepatide is what the bulk of our weight management program runs on.

Most folks in our program will not need anything more pharmacologically complex than tirzepatide for years to come. That is the right framing for what comes next.

The three receptors, in one paragraph

Retatrutide simultaneously engages three receptors. The first two it shares with the existing class. The third is new.

GCGR is the receptor neither semaglutide nor tirzepatide reaches. Everything that distinguishes retatrutide on the data — the hepatic-fat reduction, the lipid drops, the pharmacologic ketosis we'll get to in a moment — flows from that third arm.

Retatrutide: what's distinctive

Retatrutide is a 39-amino-acid peptide with a fatty-diacid lipidation that gives it the half-life for once-weekly subcutaneous injection — the same engineering trick semaglutide uses. The molecule is deliberately designed with lower glucagon-receptor potency relative to its GLP-1 and GIP potency, so that GLP-1-driven insulin secretion offsets glucagon's classic glycogenolytic effect. Phase 2 confirmed the design works as intended: no excess hyperglycemia despite the glucagon arm, and prediabetic patients reverted to normoglycemia in 72% at the higher doses.

The clinically interesting mechanistic signature shows up in the MASLD trial data. β-hydroxybutyrate — the dominant ketone the liver produces when it is oxidizing fat for fuel — rose 78 to 181 percent across the active dose groups. That is pharmacologic ketosis without carbohydrate restriction. The liver is being instructed to oxidize fat. That is the glucagon arm doing the work no other class member can do, and it is the molecular reason retatrutide should outperform the dual agonists on hepatic and visceral endpoints — not on whole-body weight, but on where the residual metabolic disease actually lives.

Phase 2 to Phase 3: the data so far

Three things stand out in the data the program has read out so far.

Weight. The Phase 2 trial published in NEJM in 2023 showed mean weight loss of 24.2% at 48 weeks at the 12 mg dose. The first Phase 3 readout — TRIUMPH-4, in a population with obesity and knee osteoarthritis — landed in December 2025 at 28.7% at 68 weeks, with mean maximum loss approaching 71 pounds. That is the largest weight-loss magnitude ever reported for a pharmacotherapy.

Hepatic and metabolic. The Phase 2a MASLD trial published in Nature Medicine in 2024 reduced liver fat by 82.4% at 12 mg over 24 weeks. Roughly nine in ten participants achieved hepatic steatosis resolution — liver fat below 5% — at 48 weeks. HOMA2-IR, the gold-standard insulin-sensitivity index, fell 69%. These numbers do not have peers in this drug class.

Atherogenic lipids. The lipid sub-analysis from ESC 2024, published in expanded form by Wen and colleagues in 2025, reported ApoB reduced 24%, non-HDL cholesterol 27%, triglycerides 41%, and apoC-III 38% at 48 weeks. The mechanism appears to converge on ANGPTL3/8 — the same pathway evinacumab targets in atherogenic dyslipidemia. Retatrutide is the first incretin-class agent to materially move ApoB and triglyceride-rich lipoproteins simultaneously.

What we are watching next: TRIUMPH-1 (general obesity, the NDA-anchor trial) and TRIUMPH-2 (obesity plus type 2 diabetes), both expected to read out in Q2 or Q3 2026. NDA filing target is Q4 2026.

The side effects worth naming

Three deserve specific attention.

GI symptoms. Nausea, diarrhea, constipation, vomiting — all class-typical, all dose-dependent, all worse with faster titration. In TRIUMPH-4 at 12 mg: nausea about 43%, diarrhea about 33%, constipation about 25%. These attenuate with time on therapy and with starting at the lower dose. Same playbook we already run on tirzepatide.

Heart rate. Retatrutide raises resting heart rate by 5 to 10 beats per minute on average, dose-dependent. The rise peaks around week 24 and attenuates. This is a class effect and matters for folks with baseline rhythm or rate concerns. Hold or slow titration if heart rate climbs more than 10 bpm above baseline.

Dysesthesia — the new signal. The December 2025 TRIUMPH-4 readout introduced something the Phase 2 data didn't predict: about one in five folks at the 12 mg dose reported abnormal sensations — paresthesia, tingling, burning skin sensations — versus less than 1% on placebo. The mechanism isn't yet characterized. The events were generally mild and rarely drove discontinuation in the trial. But this is a counseling point that doesn't exist in the tirzepatide consent conversation, and it is exactly the kind of late-emerging signal that is the reason we watch trial readouts instead of racing to compound off-label.

The phenotype where retatrutide will earn its place

The patient where retatrutide will earn its place has three converging features.

Metabolic ceiling. Tirzepatide weight loss has plateaued at the maximum dose, but ApoB is still 90 or higher, non-HDL-C is still elevated, and the residual cardiometabolic signal hasn't normalized despite respectable weight reduction.

Hepatic signal. MASLD on imaging — fibroscan, MRI-PDFF — or on labs, especially when liver fat persists despite weight loss. The 82% liver-fat reduction in the Phase 2a trial has no peer in this drug class. For the patient where the liver is the residual problem, retatrutide's third receptor is doing exactly what no current option does.

Visceral-fat-driven cardiometabolic risk. High waist-to-height ratio, central adiposity, BMI typically above 35, where the residual disease is anatomically central rather than appetite-driven.

What is not the indication: a patient whose tirzepatide is doing its job. A patient seeking maximum scale-weight loss for cosmetic reasons. A patient with a rhythm history sensitive to heart-rate elevation. The phenotype is specific. The phenotype is also not large — somewhere around 10 to 20% of our active cohort, on a working estimate.

Sidebar: the rest of the class

Three other molecules are worth knowing.

Foundayo (orforglipron, Lilly) — the first once-daily oral GLP-1, FDA-approved on April 1, 2026. About 12% mean weight loss at the top dose over 72 weeks. The big news isn't the magnitude — it's that this is a small molecule, no cold chain, no injection, no food-or-water timing restrictions. For the patient who won't or can't inject, that is a real adherence shift. It is not as effective as the injectables on weight; it is adherence-class, not magnitude-class.

Brenipatide (Lilly, investigational) — a once-monthly subcutaneous GLP-1 / GIP dual agonist. Currently in Phase 3 for alcohol use disorder, with Phase 2 trials in tobacco and opioid use disorder. The interesting beat is two: monthly dosing as an adherence tool, and the broader emergence of GLP-1-class drugs in addiction medicine.

Rybelsus (oral semaglutide) — already approved, modest efficacy compared to injectables. The original oral GLP-1, primarily a diabetes tool.

Where this lands

Tirzepatide is and remains the workhorse. Retatrutide is the right answer for a specific phenotype we are already mapping. Foundayo and brenipatide are class breadth, not class replacements. The takeaway for our clients: this remains a very active class with material change happening at the molecular level, and we are paying close enough attention to know which molecule is for which patient before the news cycle does.

One more piece of standard-of-care framing. Retatrutide is not a statin, and the lipid drops in the trial data are a downstream effect of the metabolic mechanism — not a primary lipid indication. If hyperlipidemia or dyslipidemia is your primary problem rather than a downstream feature of weight and liver disease, statin therapy remains the FDA-approved mainstay, and that conversation belongs with your primary care provider. The retatrutide lipid signal matters for the patient whose weight, liver, and lipids are all part of the same metabolic picture — not as a workaround for primary lipid management.

All of these are prescription compounds. Any conversation about adding, switching, or layering happens under physician oversight at your next check-in — never on the basis of a newsletter alone.

If you are on tirzepatide and your numbers are telling two different stories — weight responding, but the lipid or liver signal hasn't fully resolved — bring it up at your next visit. The conversation now is the difference between watching the news cycle and being on the list.

Kinetic Edge Health is a physician-led telehealth practice focused on longevity, metabolic optimization, and urological wellness. If a stack in this issue is relevant to you, book a strategy session.

Short-form dispatches on longevity, metabolic health, and men’s performance — from the founder of Kinetic Edge Health.

Telehealth practice. Prescription compounds and peptides require physician evaluation. Not available in all states.

kineticedgehealth.com · Cleveland, OH

© 2026 Kinetic Edge Health, Inc. · All rights reserved.

Not for you anymore?

Use the unsubscribe link below to stop future issues.